Answers are grounded in this paper and cite their sources.
This consensus document provides practical guidance for adopting non-HDL-C as a primary or co-primary lipid target in the Asia-Pacific region to reduce residual cardiovascular risk in atherogenic dyslipidemia.
Residual cardiovascular (CV) risk persists despite achieving low-density lipoprotein cholesterol (LDL-C) targets with lipid-lowering therapy, indicating the role of other lipid parameters. Robust evidence has shown that non-high-density lipoprotein cholesterol (non-HDL-C) confers better estimation of atherosclerotic cardiovascular disease risk than LDL-C and is increasingly recognized as a treatment target in atherogenic dyslipidemia. Whereas global guidelines have incorporated non-HDL-C as a primary or co-primary lipid target, most Asia-Pacific region (APAC) guidelines still consider it secondary to LDL-C. To address this gap, we developed a consensus document with evidence-based recommendations with the use of a modified Delphi method involving 11 experts across 10 APAC countries. This offers practical guidance on adopting non-HDL-C as a lipid target, including add-on therapies to statins for reducing non-HDL-C and CV risk in atherogenic dyslipidemia. Acknowledging regional variations in lipid targets, this document does not override local APAC guidelines but rather encourages physicians to manage non-HDL-C in alignment with those guidelines.
No takes yet. Share an insight, caveat, or question.
O’Brien et al. (2026) conducted a review in Dyslipidemia (n=11). Non-HDL-C targeted lipid-lowering therapy was evaluated. A consensus document developed by 11 experts across 10 Asia-Pacific countries provides practical guidance on adopting non-HDL-C as a lipid target in atherogenic dyslipidemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: